| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2012: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
To provide new insights into the molecular mechanisms and identify promising therapeutic targets are needed to elucidate the initiation and progression of neurological diseases. The importance of neurons, immune and glial cells in neurological diseases is becoming revealed and understood; however the pathophysiological roles of TRP channels in neurological diseases remain to be completely elucidated. In vitro and in vivo experiments demonstrate that 1) TRPC3 inhibitor Pyr3 improves outcomes after intracerebral hemorrhage in mice, 2) TRPC6 is involved in S1P-induced astrocytic responses, 3) TRPM2 contributes to LPS/ interferon gamma-induced production of nitric oxide in microglia, 4) Involvement of TRPA1 activation through oxidative modification oxaliplatin-induced acute peripheral neuropathy, 5) Activation of mitochondrial TRPV1 contributes to microglial migration, suggesting that the above-mentioned TRP channels may constitute a new therapeutic target for neurological disorders.
|
